Radiopharm Theranostics Files 6-K for December 2024
Ticker: RDPTF · Form: 6-K · Filed: Dec 20, 2024 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, sec-form-6k
TL;DR
Radiopharm Theranostics filed a 6-K for Dec 2024, confirming 20-F annual report filings.
AI Summary
Radiopharm Theranostics Limited filed a Form 6-K on December 20, 2024, reporting information for the month of December 2024. The company is a foreign private issuer and is not furnishing information under Rule 12g3-2(b). The filing indicates the company will file annual reports under cover of Form 20-F.
Why It Matters
This filing provides routine updates for investors and regulators regarding Radiopharm Theranostics' status as a foreign private issuer and its reporting obligations.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- Radiopharm Theranostics Limited (company) — Registrant
- 001-41621 (company) — Commission File Number
- 20241220 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information to the SEC.
Is Radiopharm Theranostics furnishing information under Rule 12g3-2(b)?
No, the filing explicitly states 'No' next to the indication for Rule 12g3-2(b).
What is the company's principal executive office address?
The company's principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
Does Radiopharm Theranostics file annual reports under Form 20-F or 40-F?
The filing indicates with a checkmark that the company files annual reports under cover of Form 20-F.
What is the SIC code for Radiopharm Theranostics?
The Standard Industrial Classification (SIC) code for Radiopharm Theranostics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 324 words · 1 min read · ~1 pages · Grade level 19.2 · Accepted 2024-12-20 08:00:14
Filing Documents
- ea0225466-6k_radio.htm (6-K) — 13KB
- ea022546601ex99-1_radio.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 12KB
- 0001213900-24-110770.txt ( ) — 45KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on December 20, 2024 titled: - “RAD 202 receives approval to start Phase 1 therapeutic trial” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 RAD 202 receives approval to start Phase 1 therapeutic trial 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: December 20, 2024 By: /s/ Phillip Hains Phillip Hains Company Secretary 3